Bristol-Myers Squibb (BMY) Crosses Pivot Point Support at $31.64 Financial News Network Online The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. There is potential upside of 5.6% for shares of Bristol-Myers ... |
